Lifestance Health Group, Inc. current report, 04 May 2022

Abrir documento

LifeStance Health Group, Inc. — Form 8-K Summary

Business context and reporting period

LifeStance Health Group, Inc. filed a Form 8-K with an earliest reported event date of May 4, 2022; the report was signed and filed on May 9, 2022. The filing primarily discloses new financing arrangements and furnishes the company’s first-quarter 2022 earnings materials. The first quarter ended March 31, 2022.

Financial metrics and liquidity

  • The filing text provided does not include the first-quarter revenue, profit, cash flow, margins, cash balance, or other operating metrics. Those materials were furnished as Exhibit 99.1 and are not reproduced in the supplied text.
  • On May 4, 2022, the company entered into a new senior secured credit agreement through its subsidiary, LifeStance Health Holdings, Inc.
  • The credit agreement provides for a $200.0 million senior secured term loan, a revolving facility of up to $50.0 million, and a delayed draw term loan facility of up to $100.0 million, for total potential commitments of $350.0 million.
  • The term loan proceeds are expected to repay all outstanding loans and commitments under the prior May 14, 2020 credit agreement.
  • Term loan and funded delayed-draw borrowings bear interest at adjusted term SOFR plus 4.50% or an alternate base rate plus 3.50%. Revolving borrowings bear interest at adjusted term SOFR plus 3.25% or an alternate base rate plus 2.25%.
  • Adjusted term SOFR for the term loan and delayed-draw facilities is subject to a 0.75% minimum.
  • Undrawn commitment fees apply to the delayed-draw facility at 0.50% per annum through the first anniversary of the funding date and 1.00% per annum thereafter through the second anniversary. The revolving facility carries a 0.50% per annum undrawn commitment fee.

Material changes versus the prior comparable period

  • The material disclosed change is the replacement or refinancing of the company’s existing credit arrangements with the 2022 Credit Agreement.
  • The new structure increases available financing capacity through the addition of a $100.0 million delayed draw term loan facility and provides a $50.0 million revolving facility.
  • The supplied filing text does not provide comparable first-quarter 2021 financial results or quantify changes in operating performance.

Guidance, outlook, risks, and unusual items

  • The term loan and revolving commitments were expected to be available on or before May 23, 2022, subject to customary funding conditions. The delayed-draw commitments terminate on the second anniversary of the funding date.
  • The term loan and funded delayed-draw borrowings mature on the sixth anniversary of the funding date. Revolving commitments mature on the fifth anniversary.
  • The obligations are guaranteed by Holdings and certain wholly owned subsidiaries and secured by substantially all assets of the borrower, Holdings, and subsidiary guarantors, subject to customary limitations and exceptions.
  • The credit agreement includes customary representations, affirmative and negative covenants, financial covenants, and events of default.
  • Management identified risks relating to market conditions, satisfaction of funding conditions, and the potential effect of existing indebtedness on the company’s business and growth prospects.
  • The filing contains forward-looking statements regarding availability of financing and the expected use of proceeds. Actual results or financing availability may differ materially, and the company does not undertake to update these statements except as required by law.
  • The earnings release and supplemental slide presentation were furnished under Items 2.02 and 7.01 and are not deemed filed for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.

Facts investors should verify

  1. Whether the new credit facilities were funded by the expected funding date and whether the prior credit agreement was fully repaid.
  2. Actual first-quarter 2022 revenue, profitability, cash flow, cash balance, and operating metrics in Exhibit 99.1.
  3. Outstanding borrowings, unused revolver capacity, and liquidity following the refinancing.
  4. Applicable financial covenants, collateral coverage, and any events of default under the final credit agreement.
  5. The company’s leverage, interest expense exposure, and sensitivity to rising SOFR and other market rates.
  6. Any updated guidance or outlook contained in the furnished earnings release and slide presentation.